Friday, July 10, 2026

pharma · Kidney Dysfunction · Obesity

LianBio

Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru

CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
2019
Employees
47
Programs
28
Drugs
40
Patents
0
Clinical program

HS-10345 84mg

Phase 1 · small molecule · Treatment Resistant Depressive Disorder

HS-10345 84mg for Treatment Resistant Depressive Disorder is a Phase 1 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).

← All Jian Li projects Phase 1 small molecule completed

Internal code HS-10345-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Jian Li
Phase
Phase 1
Modality
small_molecule
Indication
Treatment Resistant Depressive Disorder
Status
completed
Trials
1

Clinical trials